Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Drug Attitude Inventory in Patients with Bipolar Disorder: Psychometric Properties

Behnam Shariati 1 , Amir Shabani 2 , * , Elmira Ariana-Kia 3 , Masoud Ahmadzad-Asl 2 , Kaveh Alavi 4 , Zohreh Mousavi Behbahani 4 , Mohammad Reza Ghasemzadeh 5 , Sahar Hasani 4 , Zahra Ghiasi 6 , Fatemeh Kashaninasab 1 , Soodeh Tajik Esmaeeli 4 , Mohammad Reza Najjarzadegan 4 , Amin Kheirolahi 4 , Mahboobeh Beihaghi 4 , Seyed Vahid Shariat 7 and Shabnam Nohesara 4
Authors Information
1 Department of Psychiatry, Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Mental Health Research Center, Mood Disorders Research Group, Iran University of Medical Sciences, Tehran, Iran
3 Department of Clinical Psychology, School of Education and Psychology, Shiraz University, Shiraz, Iran
4 Department of Psychiatry, Iran Psychiatric Hospital, Tehran, Iran
5 Department of Psychiatry, AJA University of Medical Sciences, Tehran, Iran
6 Department of Psychiatry, Zahedan University of Medical Sciences, Zahedan, Iran
7 Mental Health Research Center, Department of Psychiatry, Iran Psychiatric Hospital, Tehran, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: September 2018, 12 (3); e9831
  • Published Online: July 21, 2018
  • Article Type: Original Article
  • Received: November 27, 2016
  • Revised: October 11, 2017
  • Accepted: December 16, 2017
  • DOI: 10.5812/ijpbs.9831

To Cite: Shariati B , Shabani A, Ariana-Kia E , Ahmadzad-Asl M , Alavi K , et al. Drug Attitude Inventory in Patients with Bipolar Disorder: Psychometric Properties, Iran J Psychiatry Behav Sci. 2018 ; 12(3):e9831. doi: 10.5812/ijpbs.9831.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Fassassi S, Vandeleur C, Aubry JM, Castelao E, Preisig M. Prevalence and correlates of DSM-5 bipolar and related disorders and hyperthymic personality in the community. J Affect Disord. 2014;167:198-205. doi: 10.1016/j.jad.2014.06.004. [PubMed: 24995887].
  • 2. Sharifi V, Amin-Esmaeili M, Hajebi A, Motevalian A, Radgoodarzi R, Hefazi M, et al. Twelve-month prevalence and correlates of psychiatric disorders in Iran: the Iranian Mental Health Survey, 2011. Arch Iran Med. 2015;18(2):76-84. [PubMed: 25644794].
  • 3. Najt P, Perez J, Sanches M, Peluso MA, Glahn D, Soares JC. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol. 2007;17(5):313-20. doi: 10.1016/j.euroneuro.2006.10.002. [PubMed: 17140772].
  • 4. Chang K, Howe M, Gallelli K, Miklowitz D. Prevention of pediatric bipolar disorder: integration of neurobiological and psychosocial processes. Ann N Y Acad Sci. 2006;1094:235-47. doi: 10.1196/annals.1376.026. [PubMed: 17347355].
  • 5. Shabani A, Ahmadzad-Asl M, Zangeneh K, Teimurinejad S, Kokar S, Taban M, et al. Quality of life in patients with bipolar I disorder: is it related to disorder outcome? Acta Med Iran. 2013;51(6):386-93. [PubMed: 23852843].
  • 6. Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M, et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013;15(5):457-90. doi: 10.1111/bdi.12087. [PubMed: 23755739].
  • 7. Shabani A, Teimurinejad S, Kokar S, Ahmadzad Asl M, Shariati B, Mousavi Behbahani Z, et al. Suicide Risk Factors in Iranian Patients With Bipolar Disorder: A 21- Month Follow-Up From BDPF Study. Iran J Psychiatry Behav Sci. 2013;7(1):16-23. [PubMed: 24644495]. [PubMed Central: PMC3939979].
  • 8. Ilgen MA, Bohnert AS, Ignacio RV, McCarthy JF, Valenstein MM, Kim HM, et al. Psychiatric diagnoses and risk of suicide in veterans. Arch Gen Psychiatry. 2010;67(11):1152-8. doi: 10.1001/archgenpsychiatry.2010.129. [PubMed: 21041616].
  • 9. Colom F, Vieta E, Martinez-Aran A, Reinares M, Benabarre A, Gasto C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry. 2000;61(8):549-55. doi: 10.4088/JCP.v61n0802. [PubMed: 10982196].
  • 10. Bengesser SA, Reininghaus B, Birner A, Lackner N, Kapfhammer HP, Reininghaus EZ. [Bipolar disorder and compliance]. Fortschr Neurol Psychiatr. 2013;81(7):398-400. doi: 10.1055/s-0033-1335380. [PubMed: 23856945].
  • 11. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63(5):384-90. doi: 10.4088/JCP.v63n0502. [PubMed: 12019661].
  • 12. Kampman O, Laippala P, Vaananen J, Koivisto E, Kiviniemi P, Kilkku N, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002;110(1):39-48. doi: 10.1016/S0165-1781(02)00030-6. [PubMed: 12007592].
  • 13. Mutsatsa SH, Joyce EM, Hutton SB, Webb E, Gibbins H, Paul S, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003;108(6):439-46. doi: 10.1046/j.0001-690X.2003.00193.x. [PubMed: 14616225].
  • 14. Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83(1):53-63. doi: 10.1016/j.schres.2005.10.016. [PubMed: 16529910].
  • 15. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106-13. doi: 10.4088/JCP.v69n0114. [PubMed: 18312044].
  • 16. Fischel T, Krivoy A, Kotlarov M, Zemishlany Z, Loebstein O, Jacoby H, et al. The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients. Eur Psychiatry. 2013;28(6):340-3. doi: 10.1016/j.eurpsy.2012.06.005. [PubMed: 22999435].
  • 17. Dolder CR, Lacro JP, Warren KA, Golshan S, Perkins DO, Jeste DV. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. J Clin Psychopharmacol. 2004;24(4):404-9. doi: 10.1097/ [PubMed: 15232332].
  • 18. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl. 2005;(427):29-34. doi: 10.1111/j.1600-0447.2005.00542.x. [PubMed: 15943008].
  • 19. Nielsen RE, Lindstrom E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012;22(10):747-50. doi: 10.1016/j.euroneuro.2012.02.008. [PubMed: 22440974].
  • 20. Townsend L, Floersch J, Findling RL. Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory. J Child Psychol Psychiatry. 2009;50(12):1523-31. doi: 10.1111/j.1469-7610.2009.02113.x. [PubMed: 19686336]. [PubMed Central: PMC2804771].
  • 21. Gaebel W, Riesbeck M, von Wilmsdorff M, Burns T, Derks EM, Kahn RS, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20(5):310-6. doi: 10.1016/j.euroneuro.2010.02.001. [PubMed: 20202800].
  • 22. Tamaji A, Sakai A, Sato M, Ikema Y, Matsuzaki K, Tabuse H, et al. [Development of clinical pharmacy services to improve drug adherence in psychiatric hospital patients]. Yakugaku Zasshi. 2010;130(11):1565-72. doi: 10.1248/yakushi.130.1565. [PubMed: 21048417].
  • 23. Liu-Seifert H, Osuntokun OO, Godfrey JL, Feldman PD. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369-77. [PubMed: 21049089]. [PubMed Central: PMC2962402].
  • 24. Tay SE. Compliance therapy: an intervention to improve inpatients' attitudes toward treatment. J Psychosoc Nurs Ment Health Serv. 2007;45(6):29-37. [PubMed: 17601158].
  • 25. Cheng HL, Yu YW. [Validation of the Chinese version of "the Drug Attitude Inventory"]. Kaohsiung J Med Sci. 1997;13(6):370-7. [PubMed: 9251303].
  • 26. Shabani A, Taheri A, Azadforouz S, Abbasi CN, Mousavi Z, Zangeneh K, et al. Bipolar Disorder Patients Follow-up (BDPF): methods and materials. J Res Med Sci. 2010;15(4):229-34. [PubMed: 21526087]. [PubMed Central: PMC3082809].
  • 27. Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509-16. doi: 10.2147/PPA.S40736. [PubMed: 23807840]. [PubMed Central: PMC3685450].
  • 28. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-83. doi: 10.2147/PPA.S40736. [PubMed: 6133297].
  • 29. Rossi A, Arduini L, De Cataldo S, Stratta P. [Subjective response to neuroleptic medication: a validation study of the Italian version of the Drug Attitude Inventory (DAI)]. Epidemiol Psichiatr Soc. 2001;10(2):107-14. doi: 10.1017/S1121189X00005182. [PubMed: 11526792].
  • 30. Robles Garcia R, Salazar Alvarado V, Paez Agraz F, Ramirez Barreto F. [Assessment of drug attitudes in patients with schizophrenia: psychometric properties of the DAI Spanish version]. Actas Esp Psiquiatr. 2004;32(3):138-42. [PubMed: 15168263].
  • 31. Yoon BH, Bahk WM, Lee KU, Hong CH, Ahn JK, Kim MK. Psychometric properties of korean version of drug attitude inventory (KDAI-10). Korean J Psychopharmacol. 2005;16:480-7.
  • 32. Norman GR, Streiner DL. Biostatistics: The Bare Essentials. 2nd ed. Hamilton, Ontario, Canada: B. C. Decker; 2000.
  • 33. Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Bogetto F. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry. 2008;49(2):170-6. doi: 10.1016/j.comppsych.2007.08.013. [PubMed: 18243890].
  • 34. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717-24. doi: 10.1001/archpsyc.62.7.717. [PubMed: 15997012].
  • 35. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35(2):336-46. doi: 10.1093/schbul/sbn067. [PubMed: 18586692]. [PubMed Central: PMC2659303].
  • 36. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909. [PubMed: 12416599].
  • 37. Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134(2-3):226-31. doi: 10.1016/j.schres.2011.11.008. [PubMed: 22133906].
  • 38. Kikkert MJ, Koeter MW, Dekker JJ, Burti L, Robson D, Puschner B, et al. The predictive validity of subjective adherence measures in patients with schizophrenia. Int J Methods Psychiatr Res. 2011;20(2):73-81. doi: 10.1002/mpr.335. [PubMed: 21557378].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments